Overexpression of CDCP1 is Associated with Poor Prognosis and Enhanced Immune Checkpoints Expressions in Breast Cancer

<div>Predictive value of CDCP1 for immunotherapy in BrCa cohort. (a) Expression levels of CDCP1 and PD-L1 in BrCa with various immunotherapeutic responses. (b) Comparison of predictive values of CDCP1 and PD-L1 in BrCa cohort.</div>

Journal of Oncology

fig6

Figure 6

Figure 6: Overexpression of CDCP1 is Associated with Poor Prognosis and Enhanced Immune Checkpoints Expressions in Breast Cancer 